
|Videos|August 24, 2020
Investigational Therapy in Mantle Cell Lymphoma: KTE-X19 CAR T-Cell Therapy
Author(s)Targeted Oncology
Michael Wang, MD, reacts to recent data and the potential to treat patients with relapsed or refractory mantle cell lymphoma with KTE-X19, an investigational CAR T-cell therapy.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5









































